Table 5.

Estimated costs, QALYs and ICER in PSA analyses on a 10-year time horizon.

Treatment strategy	Therapies in the order of cost		Warfarin as the common reference
	Cost (95%CI)	QALY (95%CI)	ICER
Warfarin	$14,021.90 (4,729.66–31,940.99)	5.21 (3.86–6.44)	0
Edoxaban	$27,352.70 (15,931.54–43,856.52)	6.09 (4.81–7.12)	$15,148.64
DOACs	$29,493.82 (17,750.09–6,215.20)	5.57 (4.18–6.79)	$42,977.56
Apixaban	$30,671.69 (16,849.47–48,239.88)	5.53 (4.01–6.81)	$52,030.59
Rivaroxaban	$32,179.39 (18,089.83–50,700.09)	5.41 (3.97–6.7)	$90,787.45
Dabigatran	$32,204.42 (18,392.88–50,856.49)	5.47 (4.14–6.62)	$69,932.76

DOACs, direct oral anticoagulants; QALY, quality-adjusted life-year; ICER, incremental cost-effectiveness ratio; $, United States dollar.